Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

JAMA. 2018 Sep 4;320(9):931-933. doi: 10.1001/jama.2018.7316.

Authors

Jinoos Yazdany¹, R Adams Dudley², Grace A Lin², Randi Chen³, Chien-Wen Tseng⁴

Affiliations

¹ Division of Rheumatology, University of California, San Francisco.
² Center for Healthcare Value, University of California, San Francisco.
³ Pacific Health Research and Education Institute, Honolulu, Hawaii.
⁴ Department of Family Practice and Community Health, University of Hawaii, Honolulu.

Abstract

This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents / economics*
Biosimilar Pharmaceuticals / economics*
Cost Sharing*
Financing, Personal / statistics & numerical data*
Infliximab / economics*
Insurance Coverage
Medicare Part D
Prescription Fees
United States

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Infliximab

Grants and funding